Sanford C. Bernstein Cuts Elevance Health (NYSE:ELV) Price Target to $409.00

Elevance Health (NYSE:ELV) had its price objective dropped by research analysts at Sanford C. Bernstein from $431.00 to $409.00 in a research report issued to clients and investors on Friday,MarketScreener reports. The brokerage presently has an “outperform” rating on the stock. Sanford C. Bernstein’s price objective would suggest a potential upside of 18.34% from the company’s previous close.

Several other equities analysts also recently weighed in on ELV. UBS Group set a $400.00 target price on shares of Elevance Health in a research note on Thursday. Mizuho set a $413.00 price target on Elevance Health in a report on Friday, January 9th. Wolfe Research set a $425.00 target price on Elevance Health and gave the company an “outperform” rating in a research note on Thursday, January 8th. Truist Financial set a $400.00 price objective on shares of Elevance Health in a report on Tuesday, October 14th. Finally, Guggenheim dropped their price objective on Elevance Health from $414.00 to $396.00 and set a “buy” rating for the company in a research note on Thursday. Thirteen research analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $396.90.

Elevance Health Stock Performance

NYSE:ELV opened at $345.62 on Friday. Elevance Health has a fifty-two week low of $273.71 and a fifty-two week high of $458.75. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.56 and a current ratio of 1.54. The company has a 50 day simple moving average of $351.69 and a two-hundred day simple moving average of $329.03. The company has a market capitalization of $76.81 billion, a PE ratio of 13.76, a P/E/G ratio of 1.88 and a beta of 0.51.

Elevance Health (NYSE:ELV) last announced its quarterly earnings data on Wednesday, January 28th. The company reported $3.33 EPS for the quarter, beating analysts’ consensus estimates of $3.10 by $0.23. The firm had revenue of $49.31 billion during the quarter, compared to analysts’ expectations of $49.52 billion. Elevance Health had a return on equity of 15.59% and a net margin of 2.84%.The company’s revenue for the quarter was up 9.6% compared to the same quarter last year. During the same quarter last year, the firm posted $3.84 earnings per share. Elevance Health has set its FY 2026 guidance at 25.500- EPS. Research analysts anticipate that Elevance Health will post 33.96 earnings per share for the current year.

Institutional Investors Weigh In On Elevance Health

A number of institutional investors have recently made changes to their positions in the company. Delta Investment Management LLC boosted its stake in shares of Elevance Health by 21.5% during the 4th quarter. Delta Investment Management LLC now owns 28,692 shares of the company’s stock worth $10,058,000 after acquiring an additional 5,080 shares during the last quarter. Simplicity Wealth LLC lifted its holdings in shares of Elevance Health by 20.0% in the 4th quarter. Simplicity Wealth LLC now owns 1,220 shares of the company’s stock valued at $428,000 after acquiring an additional 203 shares during the last quarter. Joel Isaacson & Co. LLC lifted its position in Elevance Health by 45.1% in the fourth quarter. Joel Isaacson & Co. LLC now owns 2,561 shares of the company’s stock worth $898,000 after buying an additional 796 shares during the last quarter. Pekin Hardy Strauss Inc. raised its position in Elevance Health by 448.0% in the 4th quarter. Pekin Hardy Strauss Inc. now owns 9,618 shares of the company’s stock worth $3,372,000 after purchasing an additional 7,863 shares during the period. Finally, Keybank National Association OH increased its stake in Elevance Health by 1.5% in the fourth quarter. Keybank National Association OH now owns 9,104 shares of the company’s stock worth $3,191,000 after purchasing an additional 132 shares during the period. Hedge funds and other institutional investors own 89.24% of the company’s stock.

Key Stories Impacting Elevance Health

Here are the key news stories impacting Elevance Health this week:

• Positive Sentiment: Q4 earnings beat consensus (EPS beat and strong profit print), which sparked an earlier rally and helped lift investor sentiment. Elevance Health (NYSE:ELV) Stock Price Up 6.3% on Strong Earnings
• Positive Sentiment: Leerink Partners nudged its price target up to $357 and maintained a “market perform” rating, a modest vote of confidence that signals upside potential from current levels. Leerink Partners adjusts price target on Elevance Health to $357
• Positive Sentiment: Consensus broker sentiment remains constructive (average “Moderate Buy”), which provides some support for the shares as analysts digest results and guidance. Elevance Health, Inc. Given Average Recommendation of “Moderate Buy”
• Neutral Sentiment: Company Q4 call and published highlights provide detail on membership shifts, margin dynamics and the drivers behind the quarter — useful for longer-term modeling but not a clear immediate catalyst. ELV Q4 2025 Earnings Call Highlights
• Negative Sentiment: Management forecast for 2026 profit came in below some Street estimates and flagged an anticipated revenue decline, which is the principal near-term headwind pressuring the stock. Elevance forecasts 2026 profit below estimates
• Negative Sentiment: Analysts and commentary highlighted margin pressures and membership shifts shaping a weaker 2026 outlook — narratives that have driven selloffs despite the quarterly beat. ELV Q4 Deep Dive: Margin Pressures and Membership Shifts
• Negative Sentiment: Regulatory context: a CMS proposal for only a modest Medicare Advantage rate increase added to near-term investor concern, contributing to a large negative move earlier in the week. Health Insurance Stock Could Rebound Off Historically Bullish Signal
• Negative Sentiment: Coverage pieces framed the results as “in line” but stressed the deteriorating outlook and ongoing industry headwinds, which has kept selling pressure on the shares after the initial post-earnings bounce. Elevance reports Q4 in line with expectations but stock drops

Elevance Health Company Profile

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.